This Texas-based biotech reported positive proof-of-concept results earlier this week and could be set to upend a number of big pharmaceutical companies if its experimental drug continues to deliver.
Teva's day in court is coming.
A dangerous new competitor for Gilead's miracle hepatitis-C drug, Sovaldi, may be on its way to market.
Merck (MRK) joins Gilead (GILD), Bristol-Myers (BMY), and AbbVie (ABBV) in the race to cure hepatitis C, but Merck may end up trailing the pack.
Morning movers in biotech and health care.
The American Association for Cancer Research meeting shines a bright light on gene testing like that performed by Myriad, and on promising late stage breast cancer treatments, including Pfizer's palbociclib.
Amarin Corporation plc (ADR) signed Japan's Kowa Pharmaceuticals as a marketing partner for Vascepa.
Time is running out for funding your IRA. Income investors should consider AbbVie, 3M, and Textainer.
Baxter announced it is splitting into two separate businesses
Promising blood thinner Eliquis hasn't quite lived up to the hype surrounding it in its early life. Can Pfizer and Bristol-Myers Squibb turn things around?